- RecruitingPHASE3
Efficacy and Safety of Infliximab for Immune Checkpoint Inhibitor Induced Colitis
This study looks at a new way to treat bowel inflammation (colitis) caused by cancer medicines called immune checkpoint inhibitors. It compares standard steroids with steroids plus a drug called infliximab to see which works best and fastest.
For: ColitisDenmark · United Kingdom - Ongoing, recruitingPhase I and Phase II (Integrated)- Other
A Phase I/II Open-label, Multi-center Study to Assess Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of AZD7789, an anti-PD-1 and anti-TIM-3 Bispecific Antibody, in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma
This study is looking at a new medicine for people in the UK with Hodgkin Lymphoma that has come back or hasn't responded to other treatments. It aims to check if the new medicine, AZD7789, is safe, what effects it has, and if it helps in treating the cancer.
For: Relapsed/Refractory Classical Hodgkin LymphomaItaly · Denmark · Spain - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase III, Randomized, Open-Label, Controlled, Multi-Center, Global Study of First-Line MEDI4736 Monotherapy and MEDI4736 in Combination with Tremelimumab Versus Standard of Care Chemotherapy in Patients with Unresectable Stage IV Urothelial Cancer
This study looks at new treatments for advanced bladder cancer that can’t be removed by surgery. It compares two new medicines, alone or together, against standard chemotherapy to see which helps people live longer and stops cancer from growing.
For: ureters · urinary bladder · and urethra)Spain · Greece - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase III, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Transarterial Chemoembolization (TACE) in Combination with either Durvalumab Monotherapy or Durvalumab plus Bevacizumab Therapy in Patients with Locoregional Hepatocellular Carcinoma (EMERALD-1)
This study is testing new ways to treat a type of liver cancer that hasn't spread far. It combines a standard treatment (TACE) with new medicines (durvalumab, sometimes with bevacizumab) to see if they help people live longer without their cancer growing.
For: Locoregional Hepatocellular Carcinoma (HCC)Italy · France · Spain - Ongoing, recruitingTherapeutic exploratory (Phase II)
A Phase II, Multicenter Induction Study with an Active Treatment Extension to Evaluate the Efficacy, Safety, and Pharmacokinetics of Vixarelimab in Patients with Moderate to Severe Ulcerative Colitis
This study is testing a new drug, called Vixarelimab, for adults with moderate to severe ulcerative colitis. It aims to see how well it works to reduce symptoms and improve the gut, as well as checking its safety and how the body handles it.
For: Ulcerative Colitis (UC)Belgium · Germany · France - Ongoing, recruitingTherapeutic exploratory (Phase II)
A Phase II, Multicentre, Open-Label Study to Assess the Efficacy and Safety of Olaparib Monotherapy and Olaparib Plus Durvalumab Combination as Neoadjuvant Therapy in Patients with BRCA Mutations and Early Stage HER2- negative Breast Cancer (OlympiaN)
This study is looking at new ways to treat a specific type of early breast cancer in people with a gene change called a BRCA mutation. It tests two medicines, olaparib alone and olaparib with durvalumab, to see how well they shrink tumours before surgery and if they are safe.
For: BRCA Mutations and Early Stage HER2-Negative Breast CancerGermany · Belgium · Austria - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase III Randomised, Double-Blind, Placebo-Controlled, Multicentre Study of Durvalumab in Combination with Chemotherapy and Bevacizumab, Followed by Maintenance Durvalumab, Bevacizumab and Olaparib in Newly Diagnosed Advanced Ovarian Cancer Patients (DUO-O).
This study looks at new treatments for advanced ovarian cancer. It combines standard chemotherapy with newer drugs, durvalumab and bevacizumab, and then adds olaparib. We want to see if this combination helps patients live longer without their cancer growing.
For: Newly diagnosed advanced (FIGO stage III-IV) high grade epithelial ovarian · fallopian or primary peritoneal cancerBelgium · Italy · Spain - AuthorisedTherapeutic use (Phase IV)
Impact of early proactive therapeutic drug monitoring on the durability and efficacy of infliximab therapy in pediatric inflammatory bowel disease: a multicenter open-label randomized-control trial
This study looks at children and teenagers with Inflammatory Bowel Disease who are starting treatment with a medicine called infliximab. Researchers want to see if checking medicine levels early helps the treatment work better and for longer, compared to usual care.
For: Inflammatory Bowel DiseaseItaly - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase III, Randomized, Placebo-controlled, Double-blind, Multi-center, International Study of Durvalumab Given Concurrently with Platinum-based Chemoradiation Therapy in Patients with Locally Advanced, Unresectable Non-small Cell Lung Cancer (Stage III) (PACIFIC2)
This study looks at a new drug called Imfinzi for people with a type of lung cancer that has spread nearby but can't be removed by surgery. It aims to see if Imfinzi, along with standard treatments like chemotherapy and radiation, helps people live longer and keeps the cancer from growing.
For: Patients with Locally Advanced · Unresectable Non-small Cell Lung Cancer (Stage III)Poland · Hungary - AuthorisedTherapeutic confirmatory (Phase III)
A Phase III, Randomised, Open-label, Global Study of Adjuvant Datopotamab Deruxtecan (Dato-DXd) in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Standard of Care, Following Complete Tumour Resection, in Participants With Stage I Adenocarcinoma Non-small Cell Lung Cancer who are ctDNA-positive or Have High-risk Pathological Features (TROPION Lung12)
This study looks at new treatments for early-stage lung cancer, specifically adenocarcinoma non-small cell lung cancer, after surgery. It compares a new drug combination, Datopotamab Deruxtecan with Rilvegostomig, or Rilvegostomig alone, against current standard treatments to see which works best at preventing the cancer from coming back.
For: Stage I adenocarcinoma non-small cell lung cancer (NSCLC) with ctDNA-positive result or high-risk pathological featureNetherlands · Spain · Hungary - AuthorisedTherapeutic exploratory (Phase II)
STARS - Prospective, bayesian, randomized, controlled, open-label, parallel-group, phase II interventional study evaluating efficacy and safety of secukinumab versus standard of care in active severe Takayasu patients
This study, called STARS, is looking at a new medicine for Takayasu arteritis, a condition that makes blood vessels inflamed. Researchers want to see if this medicine, called secukinumab (Cosentyx), works better and is safer than usual treatments for severe forms of the disease.
For: TAkayasu ARteritiSFrance